ReviewTherapeutic advances in respiratory disease2016
Influenza vaccination for patients with chronic obstructive pulmonary disease: understanding immunogenicity, efficacy and effectiveness.
Review in Therapeutic advances in respiratory disease, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 2 syntheses or guidelines pooled it, 54 citations in OpenAlex.
- Influenza vaccine effectiveness among high-risk groups: A systematic literature review and meta-analysis of case-control and cohort studies.Human vaccines & immunotherapeutics · 2018Pooled it
- Seasonal influenza vaccination in patients with COPD: a systematic literature review.BMC pulmonary medicine · 2017Pooled it
- Efficacy of oseltamivir compared with zanamivir in COPD patients with seasonal influenza virus infection: a randomized controlled trial.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2020Trial
- Metabolic reprogramming induced by CRP deficiency or human CRP transgenic in influenza-infected mice.Frontiers in immunology · 2026Article
- Mitochondrial dysfunction enhances influenza pathogenesis by up-regulating de novo sialic acid biosynthesis.Science advances · 2025Article
- Beyond Smoking: Emerging Drivers of COPD and Their Clinical Implications in Low- and Middle-Income Countries: A Narrative Review.Journal of clinical medicine · 2025Review
- Hidden in plain sight: the impact of human rhinovirus infection in adults.Respiratory research · 2025Review
- Vaccinomics and adversomics: key elements for a personalized vaccinology.Clinical and experimental vaccine research · 2024Review
- Low human beta-defensin-2 levels in the sputum of COPD patients are associated with the risk of exacerbations.BMC pulmonary medicine · 2023Article
- Prime-boost, double-dose influenza vaccine immunity in COPD: a pilot observational study.ERJ open research · 2023Article
- Biological and Genetic Mechanisms of COPD, Its Diagnosis, Treatment, and Relationship with Lung Cancer.Biomedicines · 2023Review
- Racial Disparities in Health Risk Indicators Reported by Alabamians Diagnosed with COPD.International journal of environmental research and public health · 2021Article
- Immunogenicity of trivalent seasonal influenza vaccine in patients with chronic obstructive pulmonary disease.Human vaccines & immunotherapeutics · 2021Article
- Unravelling the mechanisms driving multimorbidity in COPD to develop holistic approaches to patient-centred care.European respiratory review : an official journal of the European Respiratory Society · 2021Review
- Specialist respiratory outreach: a case-finding initiative for identifying undiagnosed COPD in primary care.NPJ primary care respiratory medicine · 2021Article
- Case-finding for COPD clinic acceptability to patients in GPs across Hampshire: a qualitative study.NPJ primary care respiratory medicine · 2021Article
- Seroprevalence of Antibodies against Diphtheria, Tetanus and Pertussis in Adult At-Risk Patients.Vaccines · 2021Article
- Influence of Hypoxia on the Epithelial-Pathogen Interactions in the Lung: Implications for Respiratory Disease.Frontiers in immunology · 2021Review
- Effects of influenza vaccination on the risk of cardiovascular and respiratory diseases and all-cause mortality.Ageing research reviews · 2020Review
- Prevalence of influenza and pneumococcal vaccination in chronic obstructive pulmonary disease patients in association with the occurrence of acute exacerbations.Journal of thoracic disease · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Influenza infection is an important cause of global mortality and morbidity with the greatest impact on older people and those with chronic disease. Patients with chronic obstructive pulmonary disease (COPD) are particularly vulnerable to influenza, with evidence for increased incidence and severity of infection. In this patient group influenza is associated with exacerbations and pneumonia which result in a significant healthcare burden and premature mortality. Influenza vaccination and in particular the use of the seasonal trivalent influenza vaccine (TIV) is recommended for patients with COPD. The evidence base for its effects in this population is, however, limited. Available data suggest that immunogenicity is variable in COPD but the underlying mechanisms are not completely understood. The contribution of age, disease severity, comorbidity and treatments to vaccine responses has only been investigated in a limited manner. Existing data suggest that key immune mechanisms governing T- and B-cell responses are adversely affected by these factors. The efficacy of TIV has been studied in a number of small clinical trials which form the basis of a Cochrane review. Here evidence for effect is conflicting depending on individual trial design and inclusions. Overall, TIV offers protection against influenza infection in the trial setting but further studies are required to stratify patients and enable prediction of inadequate responses. Larger-scale clinical studies have largely been observational and have often been conducted in consort with pneumonia vaccination. Overall the mortality benefit of TIV in COPD is suggested by a number studies but the impact on exacerbation prevention is less clear. Influenza vaccination currently plays an important role in disease prevention in COPD. However, we postulate that a more in-depth understanding of mechanisms of response in the context of a highly heterogeneous disease will lead to a more informed approach to vaccination and greater benefit for the individual patient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.